Abstract
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) presents as a morbid jawbone lesion in patients exposed to a nitrogen-containing bisphosphonate (N-BP). Although it is rare, BRONJ has caused apprehension among patients and healthcare providers and decreased acceptance of this anti-resorptive drug class to treat osteoporosis and metastatic osteolysis. We report here a novel method to elucidate the pathological mechanism of BRONJ by the selective removal of legacy N-BP from the jawbone using an intra-oral application of hydroxymethylene diphosphonate (HMDP) formulated in deformable nanoscale vesicles (DNV). After maxillary tooth extraction, zoledronate-treated mice developed delayed gingival wound closure, delayed tooth extraction socket healing and increased jawbone osteonecrosis consistent with human BRONJ lesion. Single cell RNA sequencing of mouse gingival cells revealed oral barrier immune dysregulation and unresolved pro-inflammatory reaction. HMDP-DNV topical applications to nascent mouse BRONJ lesions resulted in accelerated gingival wound closure and bone socket healing as well as attenuation of osteonecrosis development. The gingival single cell RNA sequencing demonstrated resolution of chronic inflammation by increased anti-inflammatory signature gene expression of lymphocytes and myeloid-derived suppressor cells. This study suggests that BRONJ pathology was predominantly induced by the oral N-BP and demonstrates the potential of HMDP-DNV as an effective BRONJ therapy.
Brief Summary The targeted removal of legacy bisphosphonate from the jawbone by competitive equilibrium therapy elucidated the pathological mechanism of aberrant oral barrier immunity and bisphosphonate-related osteonecrosis of the jaw (BRONJ)
Competing Interest Statement
CEM is a board member and CEM, SS and FHE hold equity in BioVinc LLC. SS, FHE and PC are employees and SS and FHE have executive management positions in BioVinc LLC. IN was a consultant of BioVinc LLC. All other authors declare no competing interests. The following patent has been granted pertaining to the results presented in this paper: US10,857,165.
Funding Statement
National Institutes of Health grant R01DE022552 (IN) National Institutes of Health grant R44DE025524 (FHE, IN) Bridge Institute at USC, Drug Discovery Center (CEM) Tohoku University Leading Young Researcher Overseas Visit Program Fellowship (HO) Japan Society for the Promotion of Science Research Fellowship for Young Scientists 19J117670 (TK) National Institutes of Health grant C06RR014529 (UCLA Facility)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The human BRONJ biopsy data were collected under the approval by the UCLA Institutional Review Board (IRB #17-000721).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
